Article
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Seminars in oncology - 1 Oct 1999
Treon S P, Shima Y, Preffer F I, Doss D S, Ellman L, Schlossman R L, Grossbard M L, Belch A R, Pilarski L M, Anderson K C
Abstract excerpt
The use of serotherapy to treat patients with plasma cell dyscrasias (PCDs) has been sought by us and others. Candidate antigens that have been targeted or proposed for targeting in PCDs include the immunoglobulin idiotype, CD19, CD38, CD54, CD126, HM1.24, and Muc-1 core protein. Unfortunately, many of these antigens are not ideal for use in serotherapy since they are not selectively expressed, are either shed or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.